Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
157
mi
from
Oklahoma City, OK
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
157
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
1227
mi
from
Abington, PA
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
1227
mi
from
Abington, PA
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
889
mi
from
Greer, SC
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
889
mi
from
Greer, SC
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
617
mi
from
Lake Jackson, TX
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
617
mi
from
Lake Jackson, TX
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
517
mi
from
Austin, TX
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
517
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
569
mi
from
Houston, TX
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
569
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
566
mi
from
Houston, TX
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
566
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
359
mi
from
DeSoto, TX
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
359
mi
from
DeSoto, TX
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
569
mi
from
Houston, TX
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
569
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
571
mi
from
San Antonio, TX
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
571
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
778
mi
from
Midvale, UT
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
778
mi
from
Midvale, UT
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
778
mi
from
Salt Lake City, UT
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
778
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
1114
mi
from
Burke, VA
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
1114
mi
from
Burke, VA
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
1104
mi
from
Manassas, VA
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
1104
mi
from
Manassas, VA
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
1182
mi
from
Norfolk, VA
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
1182
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated:  10/16/2012
Clinical Research Facility
1113
mi
from
Richmond, VA
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Enrolling
Updated: 10/16/2012
Clinical Research Facility
1113
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  10/18/2012
Intarcia Therapeutics, Inc
1322
mi
from
Hayward, CA
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 10/18/2012
Intarcia Therapeutics, Inc
1322
mi
from
Hayward, CA
Click here to add this to my saved trials
A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  10/18/2012
Intarcia Therapeutics, Inc
1322
mi
from
Hayward, CA
A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 10/18/2012
Intarcia Therapeutics, Inc
1322
mi
from
Hayward, CA
Click here to add this to my saved trials
A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Status: Enrolling
Updated:  10/18/2012
Intarcia Therapeutics, Inc
1322
mi
from
Hayward, CA
A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Status: Enrolling
Updated: 10/18/2012
Intarcia Therapeutics, Inc
1322
mi
from
Hayward, CA
Click here to add this to my saved trials
A Study in Participants With Type 1 Diabetes Mellitus
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study
Status: Enrolling
Updated:  10/19/2012
Clinical Research Facility
1169
mi
from
Los Angeles, CA
A Study in Participants With Type 1 Diabetes Mellitus
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study
Status: Enrolling
Updated: 10/19/2012
Clinical Research Facility
1169
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study in Participants With Type 1 Diabetes Mellitus
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study
Status: Enrolling
Updated:  10/19/2012
Clinical Research Facility
402
mi
from
Aurora, CO
A Study in Participants With Type 1 Diabetes Mellitus
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study
Status: Enrolling
Updated: 10/19/2012
Clinical Research Facility
402
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study in Participants With Type 1 Diabetes Mellitus
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study
Status: Enrolling
Updated:  10/19/2012
Clinical Research Facility
841
mi
from
Idaho Falls, ID
A Study in Participants With Type 1 Diabetes Mellitus
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study
Status: Enrolling
Updated: 10/19/2012
Clinical Research Facility
841
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
A Study in Participants With Type 1 Diabetes Mellitus
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study
Status: Enrolling
Updated:  10/19/2012
Clinical Research Facility
968
mi
from
Las Vegas, NV
A Study in Participants With Type 1 Diabetes Mellitus
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study
Status: Enrolling
Updated: 10/19/2012
Clinical Research Facility
968
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study in Participants With Type 1 Diabetes Mellitus
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study
Status: Enrolling
Updated:  10/19/2012
Clinical Research Facility
770
mi
from
American Fork, UT
A Study in Participants With Type 1 Diabetes Mellitus
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study
Status: Enrolling
Updated: 10/19/2012
Clinical Research Facility
770
mi
from
American Fork, UT
Click here to add this to my saved trials
A Study in Participants With Type 1 Diabetes Mellitus
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study
Status: Enrolling
Updated:  10/19/2012
Clinical Research Facility
1410
mi
from
Seattle, WA
A Study in Participants With Type 1 Diabetes Mellitus
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study
Status: Enrolling
Updated: 10/19/2012
Clinical Research Facility
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants
A Single-dose, Open-label, Randomized, 3 Period, 3 Treatment Crossover Study to Evaluate the Pharmacokinetics of Saxagliptin 5 mg and Dapagliflozin 10 mg When Coadministered to Fasted Healthy Subjects
Status: Enrolling
Updated:  10/22/2012
Icon Clinical Pharmacology
277
mi
from
Ohama, NE
Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants
A Single-dose, Open-label, Randomized, 3 Period, 3 Treatment Crossover Study to Evaluate the Pharmacokinetics of Saxagliptin 5 mg and Dapagliflozin 10 mg When Coadministered to Fasted Healthy Subjects
Status: Enrolling
Updated: 10/22/2012
Icon Clinical Pharmacology
277
mi
from
Ohama, NE
Click here to add this to my saved trials
A Pilot Study of the Effects of Diet and Behavioral Interventions on Health in Diabetics
A Pilot Study of the Effects of Diet and Behavioral Interventions on Health in Diabetics
Status: Enrolling
Updated:  10/22/2012
Osher Center for Integrative Medicine
1340
mi
from
San Francisco, CA
A Pilot Study of the Effects of Diet and Behavioral Interventions on Health in Diabetics
A Pilot Study of the Effects of Diet and Behavioral Interventions on Health in Diabetics
Status: Enrolling
Updated: 10/22/2012
Osher Center for Integrative Medicine
1340
mi
from
San Francisco, CA
Click here to add this to my saved trials
Effects of Micronutrient (Chromium) Supplementation on Diabetes
Ketosis, Vascular Inflammation, and Its Therapy (Chromium Supplementation) in Diabetic Patients
Status: Enrolling
Updated:  10/29/2012
Louisiana State University Health Sciences Center-Shreveport
429
mi
from
Shreveport, LA
Effects of Micronutrient (Chromium) Supplementation on Diabetes
Ketosis, Vascular Inflammation, and Its Therapy (Chromium Supplementation) in Diabetic Patients
Status: Enrolling
Updated: 10/29/2012
Louisiana State University Health Sciences Center-Shreveport
429
mi
from
Shreveport, LA
Click here to add this to my saved trials
A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes
A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  10/29/2012
Baylor College of Medicine
569
mi
from
Houston, TX
A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes
A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 10/29/2012
Baylor College of Medicine
569
mi
from
Houston, TX
Click here to add this to my saved trials
Role of Macronutrient Diet Composition and Infant Metabolic Outcomes in Gestational Diabetes
Role of Macronutrient Diet Composition on Maternal and Infant Metabolic Outcomes in Gestational Diabetes
Status: Enrolling
Updated:  10/29/2012
University of Colorado Anschutz Medical Campus
402
mi
from
Aurora, CO
Role of Macronutrient Diet Composition and Infant Metabolic Outcomes in Gestational Diabetes
Role of Macronutrient Diet Composition on Maternal and Infant Metabolic Outcomes in Gestational Diabetes
Status: Enrolling
Updated: 10/29/2012
University of Colorado Anschutz Medical Campus
402
mi
from
Aurora, CO
Click here to add this to my saved trials
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  11/5/2012
Diabetes-Endocrinology Center of Western NY
1064
mi
from
Williamsville, NY
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 11/5/2012
Diabetes-Endocrinology Center of Western NY
1064
mi
from
Williamsville, NY
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
683
mi
from
Birmingham, AL
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
845
mi
from
Chandler, AZ
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
845
mi
from
Chandler, AZ
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
856
mi
from
Glendale, AZ
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
856
mi
from
Glendale, AZ
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
853
mi
from
Phoenix, AZ
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
853
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
859
mi
from
Sun City, AZ
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
859
mi
from
Sun City, AZ
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
846
mi
from
Tempe, AZ
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
846
mi
from
Tempe, AZ
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
369
mi
from
Little Rock, AR
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
369
mi
from
Little Rock, AR
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
369
mi
from
Little Rock, AR
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
369
mi
from
Little Rock, AR
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
315
mi
from
Mountain Home, AR
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
315
mi
from
Mountain Home, AR
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
379
mi
from
Searcy, AR
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
379
mi
from
Searcy, AR
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
1175
mi
from
West Hills, CA
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
1175
mi
from
West Hills, CA
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
1158
mi
from
Newport Beach, CA
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
1158
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
1343
mi
from
Greenbrae, CA
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
1343
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
1163
mi
from
Huntington Beach, CA
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
1163
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
1139
mi
from
San Diego, CA
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
1139
mi
from
San Diego, CA
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
1178
mi
from
Sherman Oaks, CA
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
1178
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
1150
mi
from
Laguna Hills, CA
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
1150
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
1175
mi
from
Mission Hills, CA
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
1175
mi
from
Mission Hills, CA
Click here to add this to my saved trials
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
1309
mi
from
Salinas, CA
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
1309
mi
from
Salinas, CA
Click here to add this to my saved trials